IXI Ixico Plc

TIDMIXI

RNS Number : 5382X

IXICO plc

13 August 2018

13 August 2018

IXICO plc

("IXICO" or the "Company")

Existing clinical trial study contract value increases by GBP0.6m

Providing specialist data analytics and insights of medical imaging biomarkers in Huntington's disease

IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announced that it has signed an expanded scope to a current contract, with a top 10 pharmaceutical company. Additional services will be provided, increasing the value of the contract by GBP0.6m to GBP1.6m over the three year term. This new award has occurred within the first three months of the project; the original contract was announced on 14(th) May 2018.

As the lead image analysis partner in this study, IXICO will apply its proprietary approaches to data science, together with in-licenced algorithms from leading academic centres, to measure neurological outcomes in study participants. The expanded scope will see IXICO providing additional analysis based on advanced imaging modalities in a natural history study of people with early manifestation of Huntington's disease.

Giulio Cerroni, Chief Executive of IXICO, said: "I am delighted that our client has decided to expand our involvement at such an early stage of this important study. We value the strength of our relationships with pharmaceutical companies and our ability to provide them with important insights to support their efforts to bring new medicines to market."

For further information please contact:

 
 IXICO plc                                     Tel: +44 20 3763 
  Giulio Cerroni, Chief Executive Officer       7499 
  Susan Lowther, Chief Financial Officer 
 
 Shore Capital (Nomad and Broker)              Tel: +44 20 7408 
  Edward Mansfield / Anita Ghanekar / Daniel    4090 
  Bush 
 
 FTI Consulting Limited (Investor Relations)   Tel: +44 20 3727 
  Simon Conway/Mo Noonan                        1000 
 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our clients' neurodegenerative therapeutic pipeline through the application of novel medical imaging and mobile health digital technologies.

IXICO's specialist data analytics services are used by the global pharmaceutical industry to interpret brain scan data and digital biomarkers to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical trial process evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGRGGUUCRUPRPGP

(END) Dow Jones Newswires

August 13, 2018 02:00 ET (06:00 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024

Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024